The importance of good mental health and wellbeing has gained attention over the last decade due to an increased burden of disability and loss of quality of life associated with mental health conditions. Pharmacists have a significant role in the support and management of persons with mental health illnesses and in reducing the commonly associated stigma. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of mental health-related services. In addition, the handbook will be accompanied by the knowledge and skills (K&S) reference guide in mental health which identifies the K&S that pharmacists require for the provision of such services, thus offering guidance to pharmacists, academic institutions and CPD providers. Both publications will be launched at this event and they are part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Attendees will learn about:

1. The role of pharmacists in the prevention, identification, care and management of mental health illnesses;
2. Challenges and opportunities for pharmacists in addressing mental health illnesses;
3. The knowledge and skills pharmacists need to acquire to support their role in mental health.

Moderator:
- Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager, Portugal

Panelsits:
- Claire O’Reilly, Senior Lecturer School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia
- Sarira El-Den, Senior Lecturer The University of Sydney School of Pharmacy, Australia
- Jiahui (Jeff) Dong, PharmD Candidate The University of North Carolina, Eshelman School of Pharmacy, United States
- Dalia Bajis, FIP Lead for provision and partnerships, Australia

The demand for travel health and travel medicine services is rapidly growing with the return levels of international travel. Patients are frequently turning to community pharmacies for advice on disease reduction and maintaining personal health whilst travelling. Pretravel preparation is important for many reasons one of which is supporting Global Health policies and strategies.

In some countries legislation has been devolved to allow pharmacists to prescribe medication and vaccinate travellers. However, this is not the situation globally and the many countries place restrictions on this type of pharmacy practice.

Learning objectives:
- To raise the awareness of pretravel consultation service that can be provided in a community setting without prescribing or vaccination.
- To identify over-the-counter products that can be supplied to support travellers visiting a pharmacy
- Compare and contrast classes of over-the-counter products for selected conditions and identify/select appropriate patients for their use.
- Showcase the collaborations with the International Institute of Travel Medicine through membership of ISTM and completion of Certificate of Health

Moderator:
- Daragh Connolly, President Community Pharmacy Section, Ireland

Panelists:
- Derek Evans, Pharmacist Specialist in Travel Medicine Evans Travel Health consultancy, UK
- Karl Hess, Director, Community Pharmacy Practice Innovations Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California, USA
- Sheila Seed, Professor and Chair of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, USA
- Larry Goodyer, Professor of Pharmacy Practice, Leicester School of Pharmacy Faculty of Health and Life Sciences, De Montfort University, UK

Overall Aim:
To support pharmacists to play a proactive role in respiratory management of the health impact of indoor air pollution by helping to address their practice and education needs to enable them provide better patient advice and self-care.

Learning objectives:
• Identify the sources of indoor air pollution and its increasing threat to health
• Understand the short- and long-term impact of indoor air pollution particularly on children
• Understand clinical, pharmacological, and non-pharmacological treatments including self-care measures to minimize the impact of air pollution on respiratory health
• Illustrate how advocacy can impact behavior change to support adoption of better self-care practices aimed at reducing health impact of air pollution.

Moderator:
- Lina Bader, FIP Lead for Equity, sustainability policy and development International Pharmaceutical Federation, Saudi Arabia

Facilitator:
- Nour Eltahla, FIP Projects Coordinator for Equity, sustainability policy and development International Pharmaceutical Federation, Saudi Arabia

Panelists:
- Lidia Morawska, Director International Laboratory for Air Quality and Health (WHO CC for Air Quality and Health), Queensland University of Technology, Australia
- Gary WK Wong, Professor and honorary consultant, Department of Paediatrics, Chinese University of Hong Kong, Hong Kong
- Tyler Knowlton, Director of Communications, Communities, and Partnerships Plume Labs, France

Consumers throughout the world are increasingly looking to the internet to purchase their drugs. The worldwide pandemic has caused many consumers, who had not done so previously, to look to the internet for healthcare, healthcare information and medicinal products. However, at any given time, 95% of the roughly 35,000 online drug sellers worldwide operate illegally, in violation of laws and placing consumers at risk. Drugs purchased through an illegal drug seller on the internet may contain no drug, subtherapeutic levels of a drug, a completely different drug, or toxic chemicals. These websites will appear to be “pharmacies” or other “medical centres” providing credible health care, drug information and safe and approved medications, but are not and present risk to the unknowing consumer.

Regulators throughout the world are monitoring the level of nefarious drug sellers and “medical clinics” on the internet. Regulatory solutions to combat and remove the presence of these harmful vendors and sites have not been widely implemented. Public awareness is an important step, but also raising the awareness among healthcare providers, law makers and social media platforms.

Learning Objectives:
-To identify the level of illegal online drug sellers and bogus medical clinics on the internet and impact on the unsuspecting public
-To identify the barriers to overcome and better protect the public.
To identify programs and initiatives currently in place to combat misinformation, poor virtual care and falsified medication to enhance the safety and protect the internet consumer
-To encourage and support standards for virtual care.

Moderator:
-Ronald Guse, Chair FIP Regulators Forum - Canada
Panelists:
-Mike Isles,Director Alliance for Safe Online Pharmacy-EU-UK
-Justin Macy,Digital Health Senior Manager National Association of Boards of Pharmacy-USA
-Libby Baney,Senior Advisor to ASOP Global; Partner, Faegre Drinker LLP, Alliance for Safe on Pharmacy Global-USA

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión IV: Bioequivalencia - Estudios de Disolución de Formas Farmacéuticas

Sesión en Español

 Este webinar tiene como objetivo presentar los conceptos:

• Aspectos teóricos de la disolución de APIs

o   Etapas

o   Modelos

• Disolutores

o   Aparatos I-IV y aplicaciones

• Aplicaciones de los Estudios de disolución comparativa
• Metodologías de disolución con cambio de pH
• Medios biorrelevantes y bicarbonato

Moderadora:
- Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
- Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center, Chile

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that affects people of all ages. Pharmacists can play an important role in symptom management, referral to other healthcare professionals and provision of advice to improve quality of life. This event will provide an overview of the main roles pharmacists can have in supporting people living with IBS, from a community pharmacy perspective.

By the end of the session participants should be able to:
• Discuss the role of community pharmacists around IBS
• Understand the difference in symptoms between abdominal cramping pain and IBS
• Identify red flag symptoms for referral of IBS patients

Current and future practice. Policy and professional enablers and barriers

Several factors can influence digestive wellness and gut wellness, including stress, nutrition or medication. Disruptions to the microbiota homeostasis can lead to gastrointestinal symptoms and have an impact in immunity. This event will discuss dysbiosis and the role that pharmacists can have in improving gut wellness and immunity.

By the end of the session participants should be able to:

• Understand dysbiosis and gut wellness
• Identify tips to manage abdominal pain
• Understand the role of diet in immunologic modulation
• Understand the use of probiotics for gut wellness

Facilitar el acceso a los medicamentos: Bioequivalencia - Metodologías In Vitro para la Demostración de Equivalencia Terapéutica

Sesión V: Bioequivalencia - Estudios de Permeabilidad: principios, metodologías y análisis de datos

Sesión en Español

Este webinar tiene como objetivo presentar los conceptos:

• Rutas de absorción oral de fármacos
• Transportadores intestinales
• Estudios de permeabilidad in vitro
• Impacto de excipientes sobre la absorción oral de fármacos
• Aplicaciones de los estudios de permeabilidad

Moderadora:
-Talita Ferreira, FIP Coordinadora de Proyectos de bioexención en Latinoamérica, Brasil

Panelista:
-Pablo González, CEO Innovation and Biopharmaceutical Evaluation Center-Chile

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in Europe

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in South East Asia.

Hosted by "Industry-Government-Academia Collaboration Committee" in Medocal Safety Promotion Organization(MSPO)

(Call for Exhibitions): https://mspo.org/WCPST/en/call/

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in Americas region.

Substandard and falsified medicines, along with a lack of adherence to medication regimens, pose a threat to public health worldwide. It is possible to deliver pharmaceutical care services that address these challenges using digital healthcare techniques and approaches. Globally, digital health faces many challenges and concerns, despite its potential to impact pharmaceutical care.
FIP and the Global Pharmaceutical Observatory are launching a new needs assessment programme entitled "How can digital health support national pharmaceutical care delivery? A regional and global assessment of priorities and challenges", with an emphasis on medication adherence and fighting SF medicines.
This regional and global needs assessment programme will include a series of six regional events, culminating in a private global roundtable and a summary report.

Aim:
Facilitate a regional discussion about ongoing digital health interventions or solutions that detect, report, and act against false or substandard medicines, and how to facilitate patient adherence, as well as the challenges leadership bodies and nations face in implementing digital health solutions in pharmaceutical care delivery in the Western Pacific.

Current and future science. Enablers and barriers to innovation and collaboration across pharmaceutical science.

The fuel behind the advancement of precision medicine is the rapid growth of underlying technologies, from high-throughput sequencing and imaging to machine learning and clinical decision support systems. What are the cutting-edge technologies and fields, and what trends can we expect in the future?

The webinar will cover:

- Ongoing technological developments

- Examples of clinical application of the above technologies in a research context

- Thoughts on future directions of the field, and unaddressed gaps

- Changes to pharmacy education that are needed for future pharmacists to be competent in implementing precision medicine practices effectively

- Gaps and challenges in the field that pharmacists and pharmaceutical scientists could address

Asthma and chronic obstructive pulmonary disease are two common chronic respiratory diseases that affect hundreds of millions of people worldwide. Pharmacists have an important role to play in their prevention, care and management. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of chronic respiratory diseases-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of chronic respiratory diseases and its complications;
2. Identify the challenges and opportunities for pharmacists in addressing chronic respiratory diseases;
3. Identify the relevant knowledge and skills required for the delivery of chronic respiratory diseases-related services.

Cancer is the second leading cause of death globally, accounting for 9.6 million deaths, according to the World Health Organization. Pharmacists have a role to play in ensuring the prevention, in supporting patients to undergo frequent screening or even collaborate in screening campaigns for certain types of cancer, in managing oncological medication for optimal outcomes, in supporting self-care and the management of symptoms that some treatments might cause and in providing emotional support. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of cancer-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

 Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of cancer;
2. Identify the challenges and opportunities for pharmacists in addressing cancer;
3. Identify the relevant knowledge and skills required for the delivery of cancer-related services.

The World Health Organization estimate that 17.9 million people die from cardiovascular diseases each year, representing 32% of all global deaths. Pharmacists have a role to play in the prevention, care and management of cardiovascular diseases and their complications. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of cardiovascular diseases-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of cardiovascular diseases and their complications;
2. Identify the challenges and opportunities for pharmacists in addressing cardiovascular diseases;
3. Identify the relevant knowledge and skills required for the delivery of cardiovascular diseases-related services.

Current and future pharmaceutical education. Enablers and barriers to innovation and high quality education.

Among the greatest bottlenecks for the widespread implementation of precision medicine is the growing costs of the associated technologies. It also brings new challenges for health technology assessment, with cost-utility becoming more difficult to evaluate and predict at finer levels of patient stratification. What are these challenges? How could we address them? How might we go about refining precision medicine strategies to maximize cost utility?

The webinar will cover:

- The current health technology assessment stance on precision medicine applications

- What we know and what we don’t know about the cost-utility of new precision medicine approaches against the standard of care

- How costs may evolve with emerging technologies or trends

- Priorities for future health economics research in this area